Drug-targeting strategies for prostate cancer

Gil Ast*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


Prostate cancer is the most frequently diagnosed cancer in North American men and accounts for 10% of cancer-related deaths in men. Despite advances in early detection and aggressive treatment of early disease, the overall mortality rate has not appear to have fallen, indicating that the current therapies are not beneficial for life expectancy and new strategies are required. Prostate cancer is a dynamic evolving process that develops in distinct steps, with each step liable to additional genetic hits that change the cancer cell phenotype and alter the patterns of gene expression. The molecular events in prostate cancer are beginning to be understood, including altered expression of tumor suppressor genes, pro- and anti-apoptotic genes, and oncogenes associated with the progression of the disease; and specific genes that are expressed predominantly or exclusively in prostate cells, prostate cancer cells, and prostate metastasis cells. These latter genes on the level of DNA, RNA and protein products are the targets of several new approaches to prostate cancer therapy and are the focus of this review.

Original languageEnglish
Pages (from-to)455-466
Number of pages12
JournalCurrent Pharmaceutical Design
Issue number6
StatePublished - 2003


  • Androgen
  • Antisense
  • Cancer
  • Gene therapy
  • Peptidase
  • Prodrug
  • Prostate
  • Prostate specific antigen (PSA)


Dive into the research topics of 'Drug-targeting strategies for prostate cancer'. Together they form a unique fingerprint.

Cite this